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Abstract The thromhin receptor is a G protein-coupled recep- 
tor, hut the G proteins functionally coupled to this receptor in 
human platelets are not yet definitively identified. Thrombin stim- 
ulation of platelets leads to phospholipase C-mediated increases 
in intracellular calcium, and previous studies have suggested that 
the thrombin receptor is coupled to members of the G, family. We 
now demonstrate direct GTPase activation by tbrombin receptor 
activation peptide (TRAP) in human platelet membranes, and 
specific inhibition of TRAP-activated GTPase by antibodies to 
G,. These data demonstrate functional coupling of the thrombin 
receptor to a member of the G, family. 
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1. Introduction 
The serine protease thrombin has an important role in he- 
mostasis and thrombosis, inflammation and cell proliferation 
[l]. Platelet stimulation by thrombin occurs by activation of a 
recently cloned member of the seven transmembrane receptor 
family via a novel proteolytic mechanism [2,3]. Thrombin stim- 
ulation of platelets leads to increases in phospholipase C (PLC) 
activity, phosphoinositide metabolism, cytosolic calcium levels, 
protein phosphorylation, and eicosanoid formation, each of 
which appears to be mediated via heterotrimeric GTP binding 
protein(s) (G proteins) coupled to the receptor [4,5]. Platelets 
contain at least nine G, forms, but the identity of G protein(s) 
coupled to the thrombin receptor and phospholipase C (PLC) 
activation in platelets is controversial. Pertussis toxin inhibits 
thrombin-mediated phosphoinositide metabolism in permeabil- 
ized platelets [6], raising the possibility that members of the Gi 
family can partially mediate PLC activation by thrombin. How- 
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ever, Grandt and co-workers found that approximately 70% of 
platelet G protein activation by thrombin is pertussis toxin- 
insensitive [7] and Houslay et al. similarly found a significant 
pertussis-insensitive GTPase coupled to thrombin stimulation 
[8]. Studies in several different cells have shown the identity of 
‘Gr’, the pertussis-insensitive, PLC-coupled GTP binding pro- 
tein, to be a member of the G, family [9-l 11. Platelets are 
known to contain G,, which co-purifies with the thromboxane 
receptor from these cells [12] and recently has been demon- 
strated to be coupled functionally to this receptor using inhib- 
itory antibodies [13]. Using a heterologous expression system, 
Hung and colleagues demonstrated the cloned thrombin recep- 
tor couples to at least two distinct G proteins, found the G 
protein coupled to phosphoinositide hydrolysis to be pertussis 
toxin-insensitive, and suggested this G protein was a member 
of the G, family [14]. We therefore sought to demonstrate 
functional coupling of G, to the thrombin receptor, using plate- 
let membranes to study the activation of the GTPase by throm- 
bin and antibodies to G, subunits to investigate the role of G, 
and other G proteins in thrombin-activated GTPase. The data 
show (i) TRAP potently activates platelet membrane GTPase 
activity in a dose-dependent manner, (ii) this GTPase activity 
can be inhibited by anti-G, antibodies, and (iii) this inhibition 
by anti-G, is prevented by neutralization of the inhibitory anti- 
bodies with their cognate peptide. 
2. Experimental 
2.1. Materials 
[y-‘*P]GTP was a kind gift from Amersham International (5,000 
Ci/mmol; 10 pCi/,l). EGTA, MgCIZ, dithiothreitol, ATP and phospho- 
creatinine were from Sigma (St. Louis, MO). Creatine phosphokinase 
was from Calbiochem (San Diego, CA). U46619, the stable analogue 
of thromboxane A,, was from Cayman Chemical Co. (Ann Arbor, MI). 
Thrombin receptor agonist peptide (TRAP), amino acid sequence 
SFLLRNPNDKYGPF [15], was generously donated by Calbiochem. 
2.2. Platelet membrane preparations 
Platelet membranes were prepared exactly as described [13] from 
just-outdated platelet concentrates obtained from a hospital blood 
bank. Aliquots were stored at -80°C until the day of each assay, at 
which time they were thawed, diluted in 30 ~01s. of ice-cold 10 mM 
triethanolamine HCL, 5 mM EDTA, pH 7.4, and centrifuged at 
39,000 x g for 20 min. Pellets were resuspended and washed twice more 
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in the same manner, and then resuspended finally in ice-cold 10 mM 
triethanolamine-Cl, 100 nM NaCl, pH 7.4, for the assay. Protein 
concentrations were determined daily using the Bradford method 
(Bio-Rad), with BSA as a standard. Final membrane solutions used in 
each assay were consistently in the range of 0.450.55 mg/ml. 
2.3. GTPuse assay 
All experiments were done between July 4 and July 24, 1994, by 
students and faculty members of the 1994 MBL Physiology Course, 
working in pairs. Ail assay points were performed in triplicate unless 
a pipeting error was noted in writing before scintillation counting of the 
GTPase assay. in which case duplicates were used (less than 1% of total 
assay points). The high affinity GTPase in human platelet membranes 
was measured by a modification of the method of Aktories and Jakob 
[16], essentially as reported by Shenker et al. [13]. Reactions were 
conducted in a final volume of 100~1, and were initiated by the addition 
of 2045 pg of platelet membranes in a volume of 50 ~1 to tubes 
containing reaction mixture without or with specific agonists. The final 
reaction mixture contained 0.4 PM GTP, including 0.6-0.9 PCi of 
[y-“P]GTP (1.552 x lo6 dpm), as well as 100 mM NaCl, 0.1 mM 
EGTA, 2 mM MgCl,, 1 mM dithiothreitol, 0.1 mM ATP, 5 mM 
phosphocreatine, 100 U/ml creatine phosphokinase, 0.2% bovine serum 
albumin, 50 mM triethanolamine-HCl, pH 7.4, and indicated concen- 
trations of agonists (U46619 or TRAP). Reactions were terminated 
with 5% activated charcoal/20 mM phosphoric acid, and high affinity 
GTPase activity was calculated exactly as described [13] and expressed 
as pmol 3ZP released per min per mg of platelet protein. Antibody 
pretreatments were performed by combining 3-5 ~1 of antibody solu- 
tion with membrane suspensions for 60-90 min at 25°C with gentle 
agitation. For the peptide experiments, antibodies were combined with 
their cognate peptides in microcentrifuge tubes for 3045 min at 25°C 
at which time the membranes were added to the tubes for a further 
60-90 min at the same temperature. Statistical comparisons were made 
by two-tailed Student’s t-test with unequal variance, using Microsoft 
Excel. 
2.4. Antibodies, peptide untigens and membrane pretreatments 
Commercially available antibodies to the various G, subunits were 
used in initial experiments (see Table). Commercially available anti-G, 
antibodies used included; (G protein sequence used as peptide antigen; 
stock concentration): from Calbiochem: G,JG, (AA345-354; 1: 20,060); 
G. (AA385394 1:24.000): and from DuPont-NEN (G-protein se- 
quence used as peptide an&en): QL [anti-G:, G,,] (QLNLKEYNLV). 
For experiments with commercial antibodies, stocks were diluted 1: 133- 
1 : 350 directly into the platelet membrane suspension. 
After evidence of antibody inhibition was obtained with these anti- 
sera, affinity purified antibodies were used to confirm the specificity of 
observed inhibition (made and generously provided by P. Goldsmith, 
A. Spiegel and colleagues). All affinity purified antisera were against 
the C-terminal decapeptide of specific G, subunits and have been exten- 
sively characterized [13,17]. These include: QL, raised against G,,, , 
(peptide antigen = QLNLKEYNLV); AS, raised against G,,,lz (peptihe 
antigen = KENLKDCGLF); and ON. raised against G. (pentide anti- 
gen g QNNLKYIGLC). Affinity-purified antibodies weye *used at a 
final concentration of 10 pg/ml in all cases. Peptides were synthesized 
and HPLC-purified as described [13,17] and stock solutions (2.5-10 
mg/ml) were diluted as described in section 3. 
3. Results and discussion 
Initial experiments defined the platelet membrane GTPase 
dose-response to the thrombin receptor activation peptide, as 
well as to the thromboxane analog U46619 (Fig. 1). Resting 
(unstimulated) platelet membranes showed a basal GTPase ac- 
tivity of 9.88 f 0.57 pmol/min/mg platelet protein 
(mean f S.E.M., n = 25), consistent with previous reports of 
basal GTPase activity in freshly prepared platelet membranes 
[ 13,161. Stimulation of membranes with the thromboxane ana- 
log U46619 or TRAP led to a specific, dose-dependent increase 
in GTPase activity by each agonist. U46619 stimulated the 
hydrolysis of GTP with an EC,, of 4 PM and a maximal in- 
10.’ lo.6 1 O-5 10-4 
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Fig. 1. Doseeresponse curves for the activation of platelet membrane 
GTPase activity by TRAP (0) and the thromboxane A2 analogue 
U46619 (m). Stimulation of platelet GTPase activity by the throm- 
boxane analogue U46619 ledto a specific, dose-dependent increase in 
GTPase activitv. with an EC,, of 4 uM. Stimulation of membranes with 
TRAP also led-to a specific,ahose-hependent increase in GTPase, with 
an EC*,, of 6 PM. Basal GTPase activity in the absence of agonist was 
9.88 pmol/min/mg protein (dotted line; n = 25). 
crease in GTPase activity of 4.51 pmol/min/mg platelet protein 
(from 9.88 pmol/min/mg to 14.39 pmol/minlmg at 100 PM). 
TRAP also stimulated a specific, dose-dependent increase in 
GTPase activity. The EC,, for TRAP-stimulated GTPase was 
5 PM. Direct measurement of TRAP-stimulated GTPase activ- 
ity in platelets has not been reported previously, but this EC,, 
is similar to those reported for TRAP stimulation of platelet 
aggregation (1.3-7 PM) [ 18,191. Interestingly, the net maxima1 
increase in TRAP-specific GTPase activity observed was 
8.41 + 1.07 pmol/min/mg platelet protein (from 9.88 to 
18.29 + 1.51 at 100 PM TRAP), approximately twice that ob- 
served for U46619 stimulation. This suggests that the mem- 
branes have more thrombin receptors than thromboxane recep- 
tors, that the thrombin receptor couples more efficiently to the 
same number of G protein(s), or that the thrombin receptor is 
coupled to a greater number of G proteins than the throm- 
boxane receptor. 
Antisera against the C-terminal decapeptide of G, subunits 
have proven to be useful as probes for the coupling of receptors 
with their G proteins [13,17,20]. A series of experiments was 
therefore performed in an attempt to inhibit agonist-stimulated 
GTPase activity by treatment of the platelet membranes with 
antibodies raised to the carboxyl-termini of G, subunits. Such 
antibodies have previously been shown to inhibit platelet mem- 
brane GTPase activity to specific agonists [ 13,171. Initial exper- 
iments evaluated TRAP or U46619-stimulated GTPase activity 
in the absence or presence of membrane pretreatment with 
several commercially available inhibitory C-terminal antibodies 
(Table 1). Based on the dose-response curves of Fig. 1, anti- 
body inhibition of the GTPase stimulated by 10 PM of the 
respective agonist was tested. The thromboxane analogue 
U46619-stimulated GTPase activity was significantly inhibited 
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by anti-G, antibody QL (P < 0.0001). We also found lesser but 
significant inhibition of the U46619-stimulated GTPase by 
G, antibody in this experiment, but no effect of the C-terminal 
antibodies directed against G,/G,. In the experiments with 
TRAP, significant inhibition of stimulated GTPase activity was 
observed only with the anti-G, antibody QL. These experi- 
ments demonstrated an inhibitory effect of the anti-G, anti- 
body, confirmed the coupling of G, to the thromboxane recep- 
tor reported previously [13], and raised the possibility that G, 
was functionally coupled to the thrombin receptor in human 
platelet membranes. We sought next to determine the specific- 
ity of the inhibitory effect. To do so, we turned to experiments 
with affinity purified antibodies. As controls, we used antibod- 
ies preabsorbed with the peptides to which they were raised. 
The three affinity purified C-terminal G protein antibodies 
were studied next. These antibodies QL, AS, and QN, to G,,, ,, 
G1,+* and G,, respectively, have been previously well character- 
ized [ 13,171. In addition, the QL antibody to G, used is an 
affinity-purified version of the QL antibody used in the exper- 
iments in Table 1. In experiments with the affinity-purified QN 
and AS at a final concentration of 10 j&ml, specific inhibition 
of TRAP-stimulated platelet GTPase activity was not demon- 
strable (data not shown). In many experiments the antibodies 
QN and AS did produce some non-specific GTPase inhibition, 
which was independent of antibody concentration and unaf- 
fected by preabsorption of antibody with peptide. Only anti- 
body QL produced marked inhibition of agonist-stimulated 
GTPase that could be specifically reversed by preabsorption of 
the antibody with the immunizing peptide (Fig. 2). 
In the experiments with affinity purified QL, a small but 
significant effect of the antibody alone on basal membrane 
GTPase was noted, consistent with a contribution of the G, 
family to basal platelet membrane GTPase activity. This basal 
effect was reversed by pretreatment of the antibody with its 
corresponding peptide. At both TRAP concentrations tested, 
marked and significant inhibition of the agonist-stimulated 
GTPase by QL was observed (52% inhibition at 10e4M TRAP, 
46% inhibition at 10m5M TRAP). In five such experiments, the 
maximal inhibition of the TRAP-stimulated GTPase was 
64.4 & 9.4%. This partial inhibition of the platelet thrombin- 
stimulated GTPase by G, antibody is consistent with the stud- 
ies of Grandt and colleagues, who found 70% of the platelet 
thrombin-stimulated GTPase to be pertussis-insensitive [7], and 
with those of Hung et al., who found thrombin receptor-medi- 
Table 1 
Platelet membrane GTPase activity after TRAP or U46619 stimulation 
in the absence or presence of anti-GTP binding protein antibodies 
Membrane TRAP (1O-5 M) U46619 (1O-5 M) 
preincubation stimulation stimulation 
of GTPase (Net) of GTPase (Net) 
None (control) 5.29 f 0.256 4.43 f 0.093 
G,,, G, 4.57 f 0.536 5.47 f 2.90 
a”e (G,) 
3.97 f 0.518 3.27** + 0.244 
2.97* + 0.718 1.03*** f 0.138 
All activities are expressed as pmol/min/mg platelet protein. Basal activ- 
ity was 8.73 f 0.939 pmol/min/mg. One of three similar experiments is 
shown. In all such experiments, 2627.5 pug of human platelet mem- 
brane were incubated with buffer alone or anti-G, subunit antibodies, 
as explained in section 2. Two-tailed Student’s r-test, with unequal 
variance: *P = 0.013 vs. control, **P = 0.004 vs. control, ***P < 0.0001 
vs. control. All other values are not significant vs. control. 
51 
= 14- 
._ 
Q 
$3 
.= Q 
o0 12- 
“,f 
c cn .- 
hg IO_ 
&Z 
Q 
8- 
6- 
TRAP 
Antibody 
Peptide 
Fig. 2. Specific inhibition of TRAP-stimulated platelet GTPase activity 
by anti-G, antibody. Basal (first three bars) and TRAP-stimulated 
GTPase activity in the absence or presence of preincubation with anti- 
G, antibody QL is shown. QL antibody had a small but significant 
inhibitory effect on basal GTPase activity (*P = 0.03) while peptide- 
preabsorbed QL did not. The QL antibody markedly inhibited TRAP- 
stimulated GTPase activity at both 10e4 and 10m5 M TRAP 
(**P = 0.0007; ***P = 0.04). This inhibition was reversed by preincu- 
bation of the antibody solution with cognate peptide in each case. One 
of three similar experiments is shown. 
ated phosphoinositide hydrolysis occurred via a pertussis toxin- 
insensitive G protein [ 141. Pretreatment of the QL solution with 
10 pug/ml of the peptide used to raise the antibody caused rever- 
sal of the antibody inhibition of TRAP-stimulated GTPase at 
both concentrations of TRAP tested. 
The data presented demonstrate that thrombin receptor acti- 
vation peptide activates platelet membrane GTPase activity in 
a dose-dependent manner, which can be inhibited by the anti- 
G, antibody QL in a specific fashion. These data are consistent 
with functional coupling of the human platelet thrombin recep- 
tor to one or more members of the G, family. However, the 
data do not exclude coupling of the thrombin receptor to other 
G, subunits since at the lO,@ml concentration of antibody QL 
tested, on average 36% stimulation of GTPase activity by 
TRAP was still observed. Significantly higher concentrations 
of antibody have been used in similar studies previously [ 13,171 
and might very well demonstrate specific inhibition by other G, 
antibodies. In fact, based on previous studies, we would predict 
some of the residual TRAP GTPase is due to coupling to G, 
[68,14], though this remains to be demonstrated. A recent 
study by Offermanns and colleagues used photolabeling tech- 
niques to demonstrate thrombin receptor association with both 
G, and G,, family members in platelet membranes [21]. In 
CCL39 fibroblasts, the thrombin receptor recently has been 
found to stimulate calcium mobilization and DNA synthesis by 
members of the G, and G, families [22]. Hung and colleagues 
found phosphoinositide metabolism coupled to a pertussis 
toxin-insensitive G protein in a heterologous expression system, 
suggesting the involvement of G, [14]. However, the data here 
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are the first to demonstrate direct coupling of the thrombin 
receptor to G, GTPase activity in any cell. It is not yet clear 
which member(s) of the G, family are involved, especially since 
the presence of G,, in platelets is controversial [5,23]. It next 
will be important to determine which G proteins other than 
those of the G, family are functionally coupled to the thrombin 
receptor. It will also be important to understand whether indi- 
vidual thrombin receptors routinely activate several different 
G proteins, and/or if specific thrombin receptor subtypes exist 
that couple to distinct G proteins. 
[5] Brass, L.F., Hoxie. J.A. and Manning. D.R. (1993) Thromb. 
Haemost. 70, 217-223. 
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